Tectonic Therapeutic (TECX) Common Equity (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Common Equity data on file, last reported at $230.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at $230.4 million, down 23.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $230.4 million (down 23.46% YoY), and the FY2025 annual result was $251.3 million, up 78.53% from the prior year.
• Common Equity declined to $230.4 million in Q1 2026 per TECX's latest filing, from $251.3 million in the prior quarter.
• Over five years, Common Equity peaked at $301.0 million in Q1 2025 and troughed at -$99.6 million in Q1 2024.
• A 5-year average of $100.7 million and a median of $140.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 181.33% in 2023, then jumped 402.32% in 2025.
• A 5-year view of Common Equity shows it stood at -$45.7 million in 2022, then plunged by 85.39% to -$84.6 million in 2023, then soared by 266.33% to $140.8 million in 2024, then soared by 78.53% to $251.3 million in 2025, then dropped by 8.32% to $230.4 million in 2026.
• Business Quant data shows TECX's Common Equity at $230.4 million in Q1 2026, $251.3 million in Q4 2025, and $267.5 million in Q3 2025.